Lilly’s JAK2 inhibitor from $2.3bn acquisition shows early promise
Eli Lilly’s type II JAK2 inhibitor, which it acquired through the $2.3bn acquisition of Ajax Therapeutics earlier this year, has …
Post
-
-
Choosing a drug development partner in 2026: A practical selection framework
For emerging and mid-sized biopharma companies, selecting a drug development partner is now a strategic decision that can determine whether …
-
Incyte reports tafasitamab combo benefit in Phase III frontMIND study
Incyte has reported that its pivotal Phase III frontMIND study showed benefits when Monjuvi / Minjuvi (tafasitamab) was combined with …
-
Clinical trial statistics gets an AI-era overhaul
For much of the pharmaceutical industry's discussion around artificial intelligence (AI), attention has focused on drug discovery. Yet as sponsors …
-
Lilly reports Phase III BRUIN CLL-322 trial results for Jaypirca combo
Eli Lilly and Company has reported results from the BRUIN CLL-322 Phase III trial, assessing Jaypirca (pirtobrutinib), a non-covalent bruton …
-
Clinical trial statistics gets an AI-era overhaul
For much of the pharmaceutical industry's discussion around artificial intelligence (AI), attention has focused on drug discovery. Yet as sponsors …
-
Lilly reports Phase III BRUIN CLL-322 trial results for Jaypirca combo
Eli Lilly and Company has reported results from the BRUIN CLL-322 Phase III trial, assessing Jaypirca (pirtobrutinib), a non-covalent bruton …
-
Takeda’s oral TYK2 blocker outperforms Sotyktu in PsA trial
Takeda’s oral tyrosine kinase 2 (TYK2) inhibitor has outperformed Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque …
-
Optimism associated with decreased dementia risk
According to the World Health Organization (WHO), approximately 57 million people had dementia globally in 2021. Although the major risk …
-
Peptide drug conjugates: How the Indena and Chemi partnership is delivering
The pharmaceutical industry is investing heavily in therapies capable of delivering high-potent treatments to diseased cells while limiting damage to …
-
J&J reports data from Phase II/III ENERGY trial for wAIHA
Johnson & Johnson (J&J) has reported the first outcomes from the Phase II/III ENERGY trial, indicating that Imaavy (nipocalimab-aahu) led …
-
Novo Nordisk identifies unauthorised data access from trials
Novo Nordisk has identified that certain patient information from some of its clinical trials was accessed and copied externally in …
-
Podcast: Championing the next generation of life sciences talent, a NIHR perspective
With so much innovation happening within the life sciences sector, now is arguably the perfect time for new faces to …
-
Real-world analysis links sleep apnoea to heightened risk of glaucoma
Obstructive sleep apnoea (OSA) is a condition characterised by repeated cessation of breathing during sleep, caused by collapse of the …
-
Clinical trials vital for UK to access innovative medicines, expert says
UK patients cannot expect to access approved innovative medicines if the country does not adequately contribute to clinical trials, an …
